Simple, kidney patients with the highest magnesium levels( upper end of normal range) have the lowest odds of mortality and survival advantage based on current research.
Supplemental calcium is linked with an increase in heart disease and heart attacks. Supplemental calcium is not recommended by the National Kidney
Foundation(NKF) or the American Heart Association(AHA) if it can be avoided.
Albutrix S3 and S4 are the only keto acid analogs that allow patients to comply with 2020 recommendations and not be on a calcium-restricted diet. Patients should always take the keto acid analog with the lowest amount of calcium they can tolerate.
Calcium-based keto acid analogs that contain over 200 mg of calcium are typically only used by stage 5 patients. Over 20 countries restrict the use of calcium-based keto analogs to stage 5 patients only. Albutrix follows these guidelines as well. Albutrix S5 is only recommended for stage 5 patients. Other keto acid analogs may not carry warning labels and go against the advice of the NKF and AHA. Patients and caregivers should be aware of current recommendations.
We do not recommend going against the advice of the NKF or AHA. Magnesium intake is not restricted by the NKF or AHA, but calcium is.